Allogene Therapeutics Q3 EPS $(0.37) Beats $(0.52) Estimate, Sales $43.00K Beat $10.00K Estimate
Portfolio Pulse from mahesh@benzinga.com
Allogene Therapeutics reported Q3 earnings per share (EPS) of $(0.37), beating the analyst consensus estimate of $(0.52) by 28.85%. This is a 36.21% increase over losses from the same period last year. The company also reported quarterly sales of $43.00K, beating the analyst consensus estimate of $10.00K by 330.00%, despite a 12.24% decrease from the same period last year.
November 02, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Allogene Therapeutics reported better than expected Q3 earnings and sales, despite a YoY decrease in sales. This could potentially have a positive impact on the company's stock.
Allogene Therapeutics reported better than expected Q3 earnings and sales, which is generally a positive signal for investors. However, the YoY decrease in sales might be a concern for some investors. Overall, the news is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100